Host: Rabbit
Target Protein: CD274
Immunogen Range: 201-290/290
Clonality: Polyclonal
Isotype: IgG
Entrez Gene: 60533
Swiss Prot: Q9EP73
Source: KLH conjugated synthetic peptide derived from mouse CD274
Purification: Purified by Protein A.
Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Background:
Size: 100ul
Concentration: 1ug/ul
Applications:
WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
Predicted Molecular Weight: 32
Cross Reactive Species:
Mouse
Rat
For research use only. Not intended for diagnostic or therapeutic use.
- Nie, Ding. et al. The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor. 2021 Oct 13Read more>>
- Wenyue Zhao. et al. EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma. INT IMMUNOPHARMACOL. 2022 Sep;110:109031Read more>>
- Xin YAN. et al. PD-1/PD-L1 inhibition promotes hepatic regeneration in small-for-size liver following extended hepatectomy. CYTOKINE. 2022 Nov;159:156017Read more>>
- Zengwei Chen. et al. Quantitative analysis of multiple breast cancer biomarkers using DNA-PAINT. ANAL METHODS-UK. 2022 AugRead more>>
- Sun, Xinxin. et al. 0.1% Nano-silver mediates PD-1/PD-L1 pathway and alleviates chronic apical periodontitis in rats. ODONTOLOGY. 2022 Sep;:1-11Read more>>
- Shifa Zhang. et al. Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD-L1, IDO, TIM-3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma. THORAC CANCER. 2022 OcRead more>>
- Jie Hao. et al. Multifunctional miR181a nanoparticles promote highly efficient radiotherapy for rectal cancer. MATER TODAY ADV. 2022 Dec;16:100317Read more>>
- Wang Danyu. et al. Enrichment and sensing tumor cells by embedded immunomodulatory DNA hydrogel to inhibit postoperative tumor recurrence. NAT COMMUN. 2023 Jul;14(1):1-17Read more>>
- Huawei Li. et al. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment. PHYTOMEDICINE. 2023 Nov;:155189Read more>>
- Meiying Song. et al. Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma. INT IMMUNOPHARMACOL. 2024 Mar;129:111601Read more>>
- Huan Gao. et al. Platinum-based neoadjuvant chemotherapy upregulates STING/IFN pathway expression and promotes TILs infiltration in NSCLC. FRONT ONCOL. 2024; 14: 1346225Read more>>
Mouse spleen lysates probed with CD274 Polyclonal Antibody, unconjugated (bs-1103R) at 1:300 overnight at 4°C followed by a conjugated secondary antibody at 1:10000 for 90 minutes at 37°C.
Formalin-fixed and rat lung tissue labeled with Anti-B7-H1/PD-L1/CD274 Polyclonal Antibody, Unconjugated(bs-1103R) at 1:200 followed by conjugation to the secondary antibody and DAB staining
Lane 1: Recombinant mouse PD-L1 protein, C-His (HEK293)(bs-43633P) probed with PD-L1 Polyclonal Antibody, Unconjugated (bs-1103R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at room temperature for 60 min.